Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Final Results

29th Jul 2009 07:30

RNS Number : 4284W
Renishaw PLC
29 July 2009
 



29th July 2009

Renishaw plc and subsidiary undertakings

Preliminary announcement of results for the year ended 30th June 2009

CONSOLIDATED INCOME STATEMENT

2009

2008

£'000

£'000

Revenue

171,247

201,157

Cost of sales

(101,064)

(106,759)

Gross profit

70,183

94,398

Distribution costs

(41,559)

(35,694)

Administration costs, excluding exceptional items

(22,633)

(21,369)

Operating profit before exceptional items

5,991

37,335

Exceptional items:

Redundancy costs

(4,121)

-

Pension curtailment credit

-

1,344

Operating profit

1,870

38,679

Financial income

8,754

9,194

Financial expenses

(6,219)

(5,070)

Share of profits of associates

317

256

Profit before tax

4,722

43,059

Income tax expense

(1,124)

(8,443)

Profit for the year

3,598

34,616

Profit attributable to equity shareholders

3,871

34,716

Minority interest

(273)

(100)

3,598

34,616

*************************

Adjusted earnings per share (excluding exceptional items)

9.3P

45.9p

Earnings per share (basic and diluted)

4.9P

47.6p

Dividend per share arising in respect of the year

7.76P

25.39p

  

CONSOLIDATED BALANCE SHEET

at 30th June

2009

£'000

2008

£'000

Assets

Property, plant and equipment

73,583

68,766

Intangible assets

27,683

19,085

Investments in associates

7,085

6,788

Deferred tax assets

14,165

10,025

Other receivables

4,020

-

Total non-current assets

126,536

104,664

Current assets

Inventories

29,156 

34,220 

Trade receivables

24,057 

 42,803 

Current tax

1,626

 490 

Other receivables

4,335

5,036

Cash and cash equivalents

20,488

38,183

Total current assets

79,662

120,732

 

 

Current liabilities

Trade payables

6,588

12,691

Current tax

910

2,178

Provisions

656

824

Other payables

13,339

14,351

Total current liabilities

21,493

30,044

Net current assets

58,169

90,688

Non-current liabilities

Employee benefits

22,458

11,055

Deferred tax liabilities

10,618

12,382

Other payables

7,849

5,270

Total non-current liabilities

40,925

28,707

Total assets less total liabilities

143,780

166,645

Equity

Share capital

14,558

14,558

Share premium

42

42

Currency translation reserve

1,822

1,574

Cash flow hedging reserve

(5,415)

(4,252)

Retained earnings

132,755

154,403

Total equity attributable to shareholders

143,762

166,325

Minority interest

18

320

143,780

166,645

  

CONSOLIDATED STATEMENT OF CASH FLOW

 
2009
£'000
 
2008
£'000
Cash flows from operating activities
 
 
 
 
Profit for the year
3,598
 
 34,616 
 
 
 
 
Adjustments for:
 
 
 
Amortisation of development costs
4,433
 
2,743
Amortisation of other intangibles
1,441
 
1,512
Depreciation
8,890
 
8,061
Loss/(profit) on sale of property, plant and equipment
151
 
(1,042)
Share of profits from associates
(317)
 
(256)
Pension curtailment credit
-
 
(1,344)
Financial income
(8,754)
 
(9,194)
Financial expenses
6,219
 
5,070
Tax expense
1,124
 
8,443
 
13,187
 
13,993
 
 
 
 
Decrease in inventories
5,064
 
1,958
Decrease/(increase) in trade and other receivables
28,167
 
(2,733)
(Decrease)/increase in trade and other payables
(12,026)
 
5,916
Difference between pension service cost and contributions
-
 
(58)
(Decrease)/increase in provisions
(168)
 
131
 
21,037
 
5,214
 
 
 
 
Income taxes paid
(6,368)
 
(6,902)
 
 
 
 
Cash flows from operating activities
31,454
 
46,921
 
 
 
 
Investing activities
 
 
 
Purchase of property, plant and equipment
(11,005)
 
(5,133)
Development costs capitalised
(6,618)
 
(5,497)
Purchase of other intangibles
(7,503)
 
(1,319)
Purchase of business
-
 
(482)
Investment in associate
(400)
 
-
Sale of property, plant and equipment
259
 
1,421
Interest received
1,161
 
1,743
Dividend received from associate
80
 
80
 
 
 
 
Cash flows from investing activities
(24,026)
 
(9,187) 
 
 
 
 
Financing activities
 
 
 
Interest paid
(255)
 
(141) 
Dividends paid
(15,649)
 
(17,164) 
 
 
 
 
Cash flows from financing activities
(15,904)
 
(17,305)
 
 
 
 
Net (decrease)/increase in cash and cash equivalents
(8,476)
 
20,429
Cash and cash equivalents at beginning of the year
38,183
 
20,761 
Effect of exchange rate fluctuations on cash held
(9,219)
 
(3,007)
 
 
 
 
Cash and cash equivalents at end of the year
20,488
 
38,183 

 

CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSE

2009

£'000

2008

£'000

 

Foreign exchange translation differences

248

1,784

Actuarial loss in the pension schemes

(13,032)

(20,541)

Effective portion of changes in fair value of cash flow hedges

(1,615)

(8,469)

Deferred tax on income and expense recognised in equity 

3,614

7,999

Expense recognised directly in equity

(10,785)

(19,227)

Profit for the year

3,598

34,616

Total recognised income and expense for the year

(7,187)

15,389

Attributable to:

Equity shareholders

(6,914)

15,489

Minority interest

(273)

(100)

(7,187)

15,389

REVENUE ANALYSIS

2009

£'000

2009 at

2008 exchange

rates

£'000

2008

£'000

Continental Europe

63,222

61,056

77,219

Far East, including Japan & Australia

52,006

42,370

59,536

North & South America

40,071

35,856

46,644

Rest of World

4,689

4,650

5,738

UK and Ireland

11,259

11,259

12,020

Total Group revenue

171,247

155,191

201,157

*************************

NOTES:

 

1. The group financial statements consolidate those of the Company and its subsidiaries (together referred to as the "Group") and equity account the Group's interests in associates.
 
The group financial statements have been prepared and approved by the directors in accordance with International Financial Reporting Standards as adopted by the EU ("adopted IFRS") and applicable law.
 
2. The financial information set out above does not constitute the Company's statutory accounts for the years ended 30th June 2009 or 2008 but is derived from those accounts. Statutory accounts for 2008 have been delivered to the registrar of companies, and those for 2009 will be delivered in due course. The auditors have reported on those accounts; their reports were (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report and (iii) did not contain a statement under section 237 (2) or (3) of the Companies Act 1985 in respect of the accounts for 2008 nor a statement under section 498 (2) or (3) of the Companies Act 2006 in respect of the accounts for 2009.
 
3. This preliminary announcement and the presentation of results will be available on the Company's website www.renishaw.com.

 

The Chairman's statement to be included in the 2009 Annual report and financial statements:

This last year has been the most difficult in the history of the Company, characterised by two different half year performances. The first half commenced with record first quarter results and a promising outlook for the year, followed by an unprecedented downturn in the ensuing period. We were forced to make hard decisions in order to position the business for this market environment, pending a return of better conditions.

The cost base had to be reduced to meet the new environment, whilst maintaining our commitment to customer service and new product development programmes. We had to take a number of measures, the most difficult and painful of which was a redundancy programme under which we had to lose 437 staff (20% of the group workforce) giving annual cost savings of £17m. In addition, staff worldwide accepted a voluntary pay reduction of 20%, equivalent to £1.25m per month, which continues until 31st December 2009, subject to possible additional payments to employees, dependent upon achievement of certain profitability levels.

In parallel there has been a programme to reduce other group overhead expenditure by £10m per annum and a continuing focus on the management of working capital, particularly inventory and debtors in order to sustain positive cash balances.

Operating results

There was a marked downturn in the second half of the year, with revenue reducing by some 37% compared with the previous year. Revenue in the second half was £68.9m (2008 £109.5m) and total revenue for the year amounted to £171.2m (2008 £201.2m). This is a 15% reduction compared with the previous year, which would have been a 23% reduction at previous year exchange rates. Revenue, with the sole exception of our spectroscopy products which showed good growth, was heavily reduced in all product lines and all main geographical sectors were affected.

Operating profit for the year before exceptional items was £6.0m (2008 £37.3m) after deducting a doubtful debt provision of £2.6m (2008 £0.4m) and £1.5m in respect of legal costs relating to patent infringement litigation in the United States (2008 £ nil) which was settled in the second half of the financial year. At previous year's exchange rates this operating profit would have been a loss of £1.9m.

After the costs of the redundancy programme amounting to £4.1m and the inclusion of the share of profits of associates of £0.3m and other financial income of £2.5m, profit before tax amounted to £4.7m compared with £43.0m for the previous year. Earnings per share were 4.9p (2008 47.6p).

Balance Sheet

Capital expenditure during the year amounted to £11.0m (2008 £5.3m), reflecting capital commitments made in the first half of the year. 

At the year end, net cash balances were £20.5m compared with £38.2m at 30th June 2008. Group inventory stood at £29.2m (2008 £34.2m) and total trade debtors were reduced to £24.1m (2008 £42.8m). Trade creditors have reduced from £12.7m to £6.6m with no extension of supplier payment dates.

Pension Fund

At the year end, the revaluation under IAS 19 accounting standard of the Group's defined benefit pension funds, which are closed to new members and for future accruals to existing members, resulted in an increase in the deficit to £22.5m from £11.1m at the previous year end, reflecting poor investment performance and changes to assumptions for liability calculations.

Queen's Award

The Company has received the Queen's Award for Enterprise: Innovation 2009. The Award has been granted for the Company's OMP400 ultra-compact high-accuracy touch probe which is used for 3D measurement on computer numerically controlled machine tools. This is the Company's thirteenth Queen's Award.

Employees

I would like to thank all our employees for their steadfast support during what has been the most challenging and demanding period in our history. They have responded magnificently to all challenges and difficulties both in the UK and overseas.

Investing for the Future

As in prior economic downturns Renishaw continues to make heavy investment in future products and this year we are accelerating our new product development to help mitigate the impact of the recession. 

A number of new metrology products and applications have been added to our established product lines during the year with a number of significant products destined to come to the market in the coming year. The metrology additions have been supplemented by the licensing of the source code for the Metris Camio CMM software and the acquisition of the business and assets of Qualis Service GmbH, a Germany CMM service and calibration business, both of which enhance the development of the Group's CMM retrofit activity.

Developing from our existing metrology base has been an increasing commitment to healthcare:

Our new range of dental products was introduced at the International Dental Exhibition in CologneGermany in March.

We acquired a 75% shareholding in Schaerer Mayfield Neuromate AG (now renamed Renishaw Mayfield SA), a company based in Switzerland, which is a leading manufacturer of surgical robots, adding to our portfolio of products for the neurosurgery market. These products were introduced at the Fifteenth Quadrennial Meeting of the World Society of Stereotactic and Functional Neurosurgery held in TorontoCanada at the end of May with very encouraging results.

The Company has increased its investment in PulseTeq Limited by 25% to a 75% shareholding. PulseTeq Limited specialises in the development of coils for the enhancement of images from MRI scanners.

Prospects

It is difficult to predict how long the current market conditions will prevail. Current activity levels are showing some signs of an improvement, but we do not anticipate returning to profitability until the second quarter of this financial year. The Group, with its strong balance sheet, portfolio of existing products and new products in development (broadening into healthcare), remains strongly positioned to meet all present demands and to respond to any increase in activity as it develops. We continue to face our long-term future with great confidence.

Dividend

The Company paid an interim dividend of 7.76p per share in April which was waived by the executive directors. However, in view of the exceptional adverse trading conditions we have encountered and the consequential impact on our results, we do not propose to pay a final dividend for the year.

We will continue to monitor our performance and intend to return to paying dividends when conditions improve. The level of such dividends and the policy for the future will be determined by the financial performance of the Group as it recovers.

 

Sir David R McMurtry, CBE, RDI, CEng, FIMechE, FREng

Chairman & Chief Executive

29th July 2009

Enquiries: B R Taylor 01453 524445

A C G Roberts 01453 524445

Registered office: New Mills, Wotton-under-Edge, Gloucestershire. GL12 8JR

Telephone: 01453 524524

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EVLFLKDBLBBD

Related Shares:

Renishaw
FTSE 100 Latest
Value8,275.60
Change26.48